These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27549744)

  • 1. Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis.
    Aoyama T; Kamata K; Kishino S
    Hemodial Int; 2017 Apr; 21(2):206-212. PubMed ID: 27549744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y; Morita K; Takeda H; Kishino S; Okumura S; Fujiuchi S
    Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of garenoxacin in severe renal failure patients.
    Yamagishi Y; Hagihara M; Hamada Y; Kimura Y; Imai H; Mikamo H
    Jpn J Antibiot; 2015 Jun; 68(3):141-50. PubMed ID: 26349115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects.
    Krishna G; Noveck R; Vargas R; Grasela D; Wang Z
    Drugs R D; 2007; 8(1):43-50. PubMed ID: 17249848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    J Clin Pharmacol; 2007 May; 47(5):628-32. PubMed ID: 17395892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.
    Homma T; Kawahara T; Mikuni H; Uno T; Sato H; Fujiwara A; Uchida Y; Fukuda Y; Manabe R; Ida H; Kuwahara N; Kimura T; Hirai K; Miyata Y; Jinno M; Yamaguchi M; Kishino Y; Murata Y; Ohta S; Yamamoto M; Watanabe Y; Yamaguchi H; Kusumoto S; Suzuki S; Tanaka A; Yokoe T; Ohnishi T; Sagara H
    Int Arch Allergy Immunol; 2019; 178(4):355-362. PubMed ID: 30759444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia.
    Yamasaki R; Kanda J; Akahoshi Y; Nakano H; Ugai T; Wada H; Kawamura K; Ishihara Y; Sakamoto K; Sato M; Ashizawa M; Machishima T; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kako S; Nishida J; Kanda Y
    Int J Hematol; 2017 Jun; 105(6):835-840. PubMed ID: 28168415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients.
    Hsaiky LM; Salinitri FD; Wong J; Jennings ST; Desai NH; Lobkovich AM; Cha R
    Nephrol Dial Transplant; 2019 Oct; 34(10):1766-1772. PubMed ID: 29992286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialyzability and pharmacokinetics of sitafloxacin following multiple oral dosing in infected hemodialysis patients.
    Tsuruoka S; Yokota N; Hayasaka T; Saito T; Yamagata K
    Ther Apher Dial; 2013 Jun; 17(3):319-24. PubMed ID: 23735148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and urine concentrations of marbofloxacin following single subcutaneous administration to cats.
    Kietzmann M; Niedorf F; Kramer S; Hoffmann M; Schneider M; Vallé M; Pankow R
    Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):83-8. PubMed ID: 21306059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of sitafloxacin against clinical isolates in 2012].
    Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
    Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of sitafloxacin against clinical isolates in 2009].
    Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
    Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.